Certara, Inc. (CERT) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Certara Inc. (NASDAQ:CERT) presented at the Baird Global Healthcare Conference, positioning itself as a leader in biosimulation software and services critical for drug discovery and development. CEO William Feehery highlighted the company's profitability with over 30% EBITDA margins and a balanced 50/50 software/services revenue split. Notably, Certara claims 90% of new drugs approved in the last decade utilized their solutions, demonstrating their significant impact on improving the efficiency and success rates of drug development, a sector plagued by nearly 90% clinical trial failure rates.

Analysis

Certara's presentation at the Baird Global Healthcare Conference reinforces its dominant and highly integrated position within the pharmaceutical R&D ecosystem. Management highlighted a critical validation point: 90% of new drugs approved in the last decade have utilized the company's biosimulation software or services, underscoring its role as an essential partner in drug development. The company's financial health is robust, demonstrated by a profitable model with EBITDA margins reported in the 30% range. Furthermore, Certara is evolving towards a balanced business mix, approaching a 50% software and 50% services revenue split, which suggests a hybrid strategy combining recurring revenue streams with high-value consultative work. This positioning is particularly compelling against the backdrop of the industry's high R&D failure rate, where nearly 90% of medicines entering clinical trials fail, positioning Certara as a key solution provider for improving efficiency and de-risking development.

Key Decisions for Investors

• Given its high market penetration and strong profitability with EBITDA margins in the 30s, investors could view Certara as a quality 'picks-and-shovels' investment for exposure to the biopharma sector, potentially offering a more defensive profile than direct investments in drug developers.
• Monitor the company's revenue mix in future reports, as continued growth in the software portion of the business could lead to higher-quality recurring revenue and potential valuation multiple expansion.
• While Certara is deeply embedded in the industry, its growth remains linked to the broader health of pharmaceutical R&D spending, which should be considered a key macroeconomic factor to watch for potential headwinds.